| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 05/18/2005 | CN1202069C Use of diterpenvid monomer compound in preparing anti-cancer drugs |
| 05/18/2005 | CN1201819C Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens |
| 05/18/2005 | CN1201817C Tumor CT antigen immune inducing agent for treating liver cancer and its prepn |
| 05/18/2005 | CN1201812C Pharmaceutical preparation containing cyclopeptide and chemotherapeutic agent or angiogenesis inhibitor |
| 05/18/2005 | CN1201780C Medicine composition for treating uterus tumour and its preparing method |
| 05/18/2005 | CN1201752C Patent Chinese medicine for preventing lung cancer and relieving tabacism and preparation method thereof |
| 05/18/2005 | CN1201749C Vaginal delivery of bisphosphonates |
| 05/17/2005 | US6894185 Substituted chiral allosteric hemoglobin modifiers |
| 05/17/2005 | US6894165 Imidazonaphthyridines |
| 05/17/2005 | US6894157 Guanylate binding protein (GBP-1) as inhibitor of cell proliferation and molecular marker for the determination of the stage of cellular differentiation |
| 05/17/2005 | US6894155 Immumodulatory protein for use in the treatment of nervous system, skin and immunological disorders |
| 05/17/2005 | US6894153 Gene Any-RF; dormancy regulatory substance, process for producing the same and cell regulator for vital cells |
| 05/17/2005 | US6894075 4′-demethyl-4′-O-substituted-1-deoxypodophyllotoxin derivative and geometric isomer thereof, process for the preparation thereof and anti-cancer composition comprising the same |
| 05/17/2005 | US6894071 Medical compositions for intravesical treatment of bladder cancer |
| 05/17/2005 | US6894067 5-heteroatom-substituted pyrazoles |
| 05/17/2005 | US6894065 For therapy of thrombosis, platelet aggregation, coagulation, cancer, inflammatory diseases or respiratory diseases |
| 05/17/2005 | US6894055 Thieno-2′,3′ -5,6pyrimido[3,4-A]-1,2,4-triazole derivatives as modulators of phoshoinositide 3-kinase |
| 05/17/2005 | US6894051 Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use |
| 05/17/2005 | US6894049 Anticancer agents; water solubility |
| 05/17/2005 | US6894041 Oxazolyl-acid amide derivatives useful as inhibitors of PDE4 isozymes |
| 05/17/2005 | US6894039 A selenium containing heterocyclic compounds that are analogs of naturally occurring thiophene, furan and pyrrole, has cytotoxic effect, use as anticarcinogenic agents |
| 05/17/2005 | US6894036 4-dedimethylaminotetracycline derivatives |
| 05/17/2005 | US6894033 Combination therapies using vitamin B12 and therapeutic agents for treatment of viral, proliferative and inflammatory diseases |
| 05/17/2005 | US6893871 Human ovarian mesothelial cells and methods of isolation and uses thereof |
| 05/17/2005 | US6893869 For treatment of cancer/tumors/fungal/viral infections; tumor associated antigens; genetic engineering |
| 05/17/2005 | US6893867 Molecular switch for regulating mammalian gene expression |
| 05/17/2005 | US6893858 Human kcnq5 potassium channel, methods and compositions thereof |
| 05/17/2005 | US6893838 DADD, death activator death domain protein |
| 05/17/2005 | US6893643 Comprises exogenous nucleotide sequences which encode exogenous amino acid sequences; infection of host cell with recombinant Yellow Fever Virus provides for expression of exogenous nucleic acid and production of antigen |
| 05/17/2005 | US6893642 Anticancer nutraceutical from spirulina |
| 05/17/2005 | US6893641 Ganoderma lucidum spores for treatment of autoimmune diseases |
| 05/17/2005 | US6893638 Methods for treating b cell lymphoma using CD80-specific antibodies |
| 05/17/2005 | US6893634 Without inflammatory or other immune response side effects; injection or implantation in tissue containing cancer growth; porous cellulose sulphate and polydimethyldiallylammonium membrane; breast and/or pancreatic tumors |
| 05/17/2005 | US6893633 Methods and compositions for promoting the maturation of monocytes |
| 05/17/2005 | CA2335492C Pyrrolo[2,3-d]pyrimidine compounds |
| 05/17/2005 | CA2306782C Isoquinolines as urokinase inhibitors |
| 05/17/2005 | CA2304987C Inhibition of an fgf-binding protein using ribozymes |
| 05/12/2005 | WO2005042727A2 Methods of organ regeneration |
| 05/12/2005 | WO2005042507A1 Bis {6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, (4e)-4-hexenoic acid} zinc salt |
| 05/12/2005 | WO2005042008A1 Agent against malignant neuroglia and agent against malignant neuroglia for animals |
| 05/12/2005 | WO2005042004A1 Use of transcription factor sox9 for the treatment of tumors expressing carcinoembryonnic antigen |
| 05/12/2005 | WO2005041856A2 Use of 2-thia-dibenzo[e, h]azulenes for the treatment and prevention of central nervous system diseases and disorders |
| 05/12/2005 | WO2005019269A3 Techniques and compositions for the diagnosis and treatment of cancer (muc1) |
| 05/12/2005 | WO2005007699A3 Human antibody molecules for il-13 |
| 05/12/2005 | WO2005002572A3 Use of [3.2.0] heterocyclic compounds and analogs thereof for the treatment of cancer, inflammation and infectious diseases |
| 05/12/2005 | WO2004084926B1 Cell- and gland-restorative and/or anti-carcinogenic liquid agave extract and method of obtaining same |
| 05/12/2005 | WO2004071530A3 Identification of cellular polypeptides differentially expressed by tumor cells |
| 05/12/2005 | WO2004067560A3 Herpes simplex vp16 protein binding polypeptides |
| 05/12/2005 | WO2004007717A8 Proteomic screen to identify disease-related biological molecules and inhibitors thereto |
| 05/12/2005 | WO2003070903A3 RNA INTERFERENCE MEDIATED INHIBITION OF GRB2-ASSOCIATED BINDING PROTEIN 2 (GAB2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 05/12/2005 | WO2002072627A8 Induction of anti-tumor cytotoxic t-lymphocytes in humans using peptide epitopes found by computer based algorithms for vaccination |
| 05/12/2005 | US20050101804 Reacting a benzophenone compound with a bromine compound in presence of phase transfer catalyst and solvent |
| 05/12/2005 | US20050101781 Eponemycin and epoxomicin analogs and uses thereof |
| 05/12/2005 | US20050101779 Antagonistic activity to alpha 4 integrin; antiinflammatory agents treating asthma, rheumatoid arthritis, inflammatory bowel diseases, lupus, diabetes; 1-[[(cyclohexyloxy)carbonyl]oxy]ethyl(2S)-2-[(2,6-dichlorobenzoyl)amino]-3-[4-[1-methyl-2,4-dioxo-1,4-tetrahydro-3-(2H)quinazolinyl]phenyl]Propionate |
| 05/12/2005 | US20050101775 Cyclic phosph(oramid)ate prodrugs having alcohol, amine, orthiol groups attached to phosphorus; camptothecins; pharmacodynamic half-life; diagnostic imaging |
| 05/12/2005 | US20050101769 CD40-interacting and TRAF-interacting proteins |
| 05/12/2005 | US20050101662 Such as coumarin, dicoumarol, 7-hydroxycoumarin (umbelliferone), 6,7- dihydroxycoumarin (exculetin), 3,6,7 trihydroxycoumarin, warfarin, or warfarin sodium; cancer, Alzheimer's disease, gout, atherosclerosis, restenosis |
| 05/12/2005 | US20050101661 Cyclooxygenase inhibitors; musculoskeletal and cardiovascular disorders; antiinflammatory agents |
| 05/12/2005 | US20050101657 Pyrrole derivatives for preventing or treating cancer sensitive to hormones; administered with luteininzing hormone releasing hormone derivative |
| 05/12/2005 | US20050101650 (4-(4-(2,3-difluorophenyl)-4H-1,2,4-triazol-3-yl)-1H-pyrrol-2-yl)(2H-pyrrol-1(5H)-yl)methanone; anticarcinogenic, antiproliferative and antimetastasis agent; inhibitors of c-Met protein kinase |
| 05/12/2005 | US20050101647 For example, 2-(1,3-benzodioxol-5-yl)-6-phenyl-1H-imidazo[4,5-b]pyridinetyrosine; kinase-inhibiting activity; use in treatment of breast cancer, prostate cancer, lung cancer or pancreatic carcinoma |
| 05/12/2005 | US20050101641 Aromatic sulfone hydroxamic acids and their use as protease inhibitors |
| 05/12/2005 | US20050101635 Delivering to an external portion of the body passageway of a patient in need of a therapeutically effective amount of an antihistamine or decongestant to treat inflammatory diseases |
| 05/12/2005 | US20050101630 4-Anilino-, phenoxy-, or phenylthio-substituted; inhibitors of specific kinase enzymes, such as MEK enzymes |
| 05/12/2005 | US20050101609 Quinazoline derivatives as kinase inhibitors |
| 05/12/2005 | US20050101595 N-containing cycloalkyl-substituted amino-thiazole derivatives and pharmaceutical compositions for inhibiting cell proliferation and methods for their use |
| 05/12/2005 | US20050101594 Compositions useful as inhibitors of protein kinases |
| 05/12/2005 | US20050101593 Phosphoric acid salt of an integrin receptor antagonist |
| 05/12/2005 | US20050101584 Selective estrogen receptor-beta ligands |
| 05/12/2005 | US20050101575 Vitamin d3 derivatives and remedies using the same |
| 05/12/2005 | US20050101571 Methods of treating cancer using a combination of drugs |
| 05/12/2005 | US20050101567 Using a sulfonamide containing compound |
| 05/12/2005 | US20050101563 Using cyclooxygenase inhbitor and fatty acid; analgesics; antiinflammatory agents; antiarthritic agents; vision defects; urogenital disorders; gastrointestinal disorders |
| 05/12/2005 | US20050101560 Method of treating an individual with methyl 1-[N6-(3-iodobenzyl)-adenin-9-yl] beta-D-ibofuronamide |
| 05/12/2005 | US20050101557 Immunostimulatory nucleic acid molecules |
| 05/12/2005 | US20050101556 Genetic engineering; Alzheimer's disease; anticancer agents |
| 05/12/2005 | US20050101554 Methods for treating and preventing infectious disease |
| 05/12/2005 | US20050101546 Increased solubility flavanolignan preparations |
| 05/12/2005 | US20050101536 Modulation of angiogenesis |
| 05/12/2005 | US20050101529 Protein modification and maintenance molecules |
| 05/12/2005 | US20050101528 Substituted (e)-styryl benzylsulfones for treating proliferative disorders |
| 05/12/2005 | US20050101527 Method for treating the central nervous system by administration of igf structural analogs |
| 05/12/2005 | US20050101524 Using arsenic oxide, or complex thereof; angiogenesis inhibitors; anticarcinogenic agents; neurodegenerative agents; antiischemic agents |
| 05/12/2005 | US20050101522 Antihyperplastic agents; antitumor agents; side effect reduction |
| 05/12/2005 | US20050100918 Mammalian receptor proteins; related reagents and methods |
| 05/12/2005 | US20050100917 Mammalian receptor proteins; related reagents and methods |
| 05/12/2005 | US20050100907 Method and medicament for inhibiting the expression of a given gene |
| 05/12/2005 | US20050100903 Screening method |
| 05/12/2005 | US20050100895 Using conditionally replication-competent adenoviruses transcription as diagnostic indicator of cell proliferative disorders of alimentary canal; tissue targeted therapy; drug delivery |
| 05/12/2005 | US20050100894 Novel mitogen activated kinase |
| 05/12/2005 | US20050100611 Administering a therapeutically effective amount of arsenic compounds, optionally along with other non-arsenic therapeutic agents, to a mammal for treating solid tumors |
| 05/12/2005 | US20050100610 Use of bioactive fraction from cow urine distillate ('Go-mutra'} as a bio-enhancer of anti-infective, anti-cancer agents and nutrients |
| 05/12/2005 | US20050100590 Liposomes encapsulating anticancer drugs and use thereof in the treatment of malignant tumours |
| 05/12/2005 | US20050100555 Synovial tissue binding peptide; amino acid sequence motifs; identify binding peptides by grafting tissue of first species into second having attenuated immunological response |
| 05/12/2005 | US20050100551 Vaccine against cancerous diseases which is based on mimotopes of antigens expressed on tumor cells |
| 05/12/2005 | US20050100547 Also a method for detecting an agent capable of binding TRAF2 binding site of sphingosine kinase by contacting cells with a putative agent and detecting an altered expression phenotype |
| 05/12/2005 | US20050100545 Mutated antibody does not possess O-linked glycosylation, nucleic acids encoding prevents N-linked glycosylation; humanized and conjugated with radionucleotide to image target cells |
| 05/12/2005 | US20050100542 Cytotoxicity mediation of cells evidencing surface expression of CD44 |
| 05/12/2005 | US20050100541 Ligands, including antibodies, showing reactivity against endocrine cells |
| 05/12/2005 | CA2544786A1 Method for producing gene transferred dendritic cells |